Aldeyra Gets First Patient Enrolled in Phase 3 Trial

- April 27th, 2017

Aldeyra Therapeutics enrolled the first patient in their Phase 3 clinical trial of ADX-102.

Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in their Phase 3 clinical trial of ADX-102 treating noninfectious anterior uveitis, with results expected by the latter half of 2018.
As quoted in the press release:

“Based on positive results from our Phase 2 clinical trial announced last year, we are excited to commence Phase 3 clinical testing of our novel aldehyde trap, ADX-102, in noninfectious anterior uveitis,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “NAU is a rare and potentially blinding ocular disorder that affects an estimated 150,000 patients in the United States. In contrast to corticosteroids, which are often used to treat NAU, ADX-102 does not appear to cause increases in intraocular pressure — a precursor to glaucoma — and thus may represent a safer therapeutic option than the current standard of care.”
ADX-102 and other product candidates generated from Aldeyra’s aldehyde trap platform sequester and facilitate the degradation of aldehydes, a class of endogenously generated pro-inflammatory mediators. In a Phase 2 clinical trial in NAU, 0.5% topical ocular ADX-102 led to the resolution of inflammation to the same degree as corticosteroid therapy, but without the increases in intraocular pressure observed in corticosteroid-treated patients.
The Phase 3 clinical trial is expected to enroll up to 100 NAU patients with active disease, randomized equally to receive either 0.5% topical ocular ADX-102 or vehicle for four weeks. Consistent with the Phase 2 trial, the primary endpoint will be the resolution of inflammation. Results of the Phase 3 trial are expected in the second half of 2018.

Click here to read the full press release.


Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply